Abstract:Purpose: Lung cancer is the most common malignancy with the highest morbidity and mortality worldwide. Low-dose computed tomography (LDCT) is one of the main tools for lung cancer screening and diagnosis. However, high false positive, high cost, over-diagnosis and radiation exposure are major drawbacks to screen pulmonary nodules by LDCT. Thus, a noninvasive diagnostic approach with high specificity and accuracy is badly needed to enhance LDCT. Liquid biopsy represent a valuable non-invasive approach when biopsy or resection is not the first choice. Till now, it is rare to see the studies on exosome-derived miRNAs as early diagnosis biomarkers to distinguish benign and malignant pulmonary nodules using small RNA sequencing. Here, we aimed to explore the diagnostic value of a panel of significantly differential expressed plasma exosomal miRNAs between benign and malignant pulmonary nodule samples in Chinese cohorts. Materials and Methods: This study was registered at Chinese Clinical Trial Registry (www.chictr.org.cn) with registration number ChiCTR1800019877. Forty-five patients including twenty-six lung adenocarcinoma and nineteen benign nodules with various pathological characteristics were enrolled as a training cohort. A test cohort consisted of sixty-two patients with twenty-four benign nodules patients similar to training cohort and thirty-eight lung adenocarcinoma. Exosomes were precipitated from the plasma, and small RNA sequencing was performed to identify the differential expressed miRNAs. A statistical model consisting of a panel of exosomal miRNAs was trained to discriminate benign nodules from cancerous ones. The model was validated in the independent test cohort, and re-confirmed in an external dataset from another Chinese cohort. Enriched Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were also performed. Results: Characteristic proteins and morphology of exosomes were characterised by western blotting, nanoparticle tracking analysis and scanning electron microscopy. Five differential expressed miRNAs (let-7b-3p, miR-101-3p, miR-125b-5p, miR-150-5p, and miR-3168) with median expression \u003e 50 were selected by LASSO-penalized regression as a linear model to classify samples into benign or maligant groups with 10-fold cross-validation to determine the model parameters. When the specificity set 94.7% and 91.7% for the training and test cohorts, respectively, the model had 57.7% and 57.9% sensitivity in both cohorts. The model was also confirmed in an external dataset with 87.5% specificity and 53.1% sensitivity. The expression of each biomarker in benign, adenocarcinoma in situ/microinvasive adenocarcinoma and invasive adenocarcinoma nodules were gradually altered. Four of the five biomarkers were gradually increased, whereas one miRNA was gradually decreased. GO and KEGG analysis demonstrated that biological process and pathways of the genes targeted by five biomarkers were associated with tumor development. Conclusions: This study using small RNA sequencing identified five plasma exosome-derived differentially expressed miRNAs as a diagnosis model to distinguish benign and malignant pulmonary nodules, which provides insights into the feasibility of exosomal miRNAs as a novel early diagnosis approach for lung adenocarcinoma. Citation Format: Di Zheng, Yang Yang, Chunyan Wu, Huizhen Wang, Jiyang Zhang, Shiyi Liu, Xiaoya Xu, Hao Chen, Dadong Zhang, Fugen Li, Jian Ni, Gening Jiang, Jianfang Xu. A panel of plasma exosomal miRNAs as diagnosis biomarker to distinguish benign and malignant nodules in non-small cell lung cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 756.

Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers

Serum Micrornas Improving the Diagnostic Accuracy in Lung Cancer Presenting with Pulmonary Nodules.

The Role of Plasma Mirnas in the Diagnosis of Pulmonary Nodules

Highly Sensitive and Specific Panels of Plasma Exosomal microRNAs for Identification of Malignant Pulmonary Nodules

MicroRNA‐based Biomarkers for Diagnosis of Non‐small Cell Lung Cancer (NSCLC)

Identification of miRNA Biomarkers for Non-small Cell Lung Cancer using Microarray Datasets and Bioinformatics Analysis

Combining Plasma Mirnas And Computed Tomography Features To Differentiate The Nature Of Pulmonary Nodules

Seven-Microrna Panel For Lung Adenocarcinoma Early Diagnosis In Patients Presenting With Ground-Glass Nodules

A panel of plasma exosomal miRNAs as diagnosis biomarker to distinguish benign and malignant nodules in non-small cell lung cancer

A Plasma Mirna-Based Classifier for Small Cell Lung Cancer Diagnosis

Two Plasma Microrna Panels for Diagnosis and Subtype Discrimination of Lung Cancer

Identification and evaluation of circulating small extracellular vesicle microRNAs as diagnostic biomarkers for patients with indeterminate pulmonary nodules

Five Micrornas in Plasma As Novel Biomarkers for Screening of Early-Stage Non-Small Cell Lung Cancer

Circulating Plasma Mirnas As Potential Biomarkers of Non-Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling

Identification of Four Plasma Micrornas As Potential Biomarkers in the Diagnosis of Male Lung Squamous Cell Carcinoma Patients in China.

Plasma Mir‐1247‐5p, Mir‐301b‐3p and Mir‐105‐5p As Potential Biomarkers for Early Diagnosis of Non‐small Cell Lung Cancer

A Classifier Integrating Plasma Biomarkers And Radiological Characteristics For Distinguishing Malignant From Benign Pulmonary Nodules

P1.11-18 A Classification-Based Machine Learning Method Reveals Exosomal miRNA Biomarkers for Patients with Pulmonary Ground Glass Nodule

Identification of Plasma Microrna-21 As a Biomarker for Early Detection and Chemosensitivity of Non-Small Cell Lung Cancer

OP0016 Development of a panel of five miRNAs as a diagnostic tool for non-small-cell lung cancer

Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC)